BioCentury
ARTICLE | Clinical News

Topsalysin: Phase III data

November 16, 2015 8:00 AM UTC

The double-blind, international Phase III PLUS-1 in 479 patients with moderate to severe BPH showed that a single intraprostatic injection of 0.6 ug/g PRX302 met the primary endpoint of improving IPSS...